GR

Green Cross Holdings

A biotech firm in biopharma, diagnostics, digital health, and consumer wellness products.

005250 | KO

Overview

Corporate Details

ISIN(s):
KR7005250006
LEI:
Country:
South Korea
Address:
경기 용인시 구성읍 동백리 (주)녹십자 303, 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Green Cross Holdings is a holding company focused on the healthcare and biotechnology industries. Its core operations are divided into four main segments: Biopharma & Innovative Technology, Diagnosis, Digital Healthcare, and Consumer Health. The Biopharma division is a key area, specializing in the development, manufacturing, and marketing of plasma derivatives, protein therapeutics, and vaccines. The company is recognized for developing the world's first pandemic hemorrhagic fever vaccine and South Korea's first flu vaccine. The Diagnosis segment provides in-vitro diagnostic services and supports clinical trials. Its Digital Healthcare platform facilitates remote medical services and monitoring, while the Consumer Health division offers functional foods and wellness products. The company maintains a global presence, exporting its products to numerous countries.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 212.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 4.6 MB
2025-06-26 00:00
Prospectus
투자설명서
Korean 4.8 MB
2025-06-26 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 54.8 KB
2025-06-25 00:00
Registration Form
[발행조건확정]증권신고서(채무증권)
Korean 15.4 KB
2025-06-20 00:00
Prospectus
[기재정정]증권신고서(채무증권)
Korean 5.5 MB
2025-06-20 00:00
Registration Form
[발행조건확정]증권신고서(채무증권)
Korean 612.7 KB
2025-06-19 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 18.1 KB
2025-06-16 00:00
Registration Form
증권신고서(채무증권)
Korean 4.7 MB
2025-06-02 00:00
Governance Information
기업지배구조보고서공시
Korean 852.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 3.9 MB
2025-04-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 29.3 KB
2025-04-25 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 92.4 KB
2025-04-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 258.1 KB
2025-04-11 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 83.3 KB

Automate Your Workflow. Get a real-time feed of all Green Cross Holdings filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Green Cross Holdings

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Green Cross Holdings via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France
ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden
ABLI
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America
ABP
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France
AB
ACADIA PHARMACEUTICALS INC Logo
Develops and commercializes innovative therapies for CNS disorders and rare diseases.
United States of America
ACAD
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America
ACHV
AC Immune SA Logo
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America
ACRS
Actinium Pharmaceuticals, Inc. Logo
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America
ATNM

Talk to a Data Expert

Have a question? We'll get back to you promptly.